IMRIS receives FDA clearance for 3 Tesla IMRISneuro


    WINNIPEG, Dec. 18, 2008 /CNW/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the
"Company") today announced that the U.S. Food and Drug Administration (FDA)
has cleared the Company's 3 Tesla IMRISneuro for sale in the U.S. IMRISneuro
is now available with either a 1.5 Tesla (1.5T) or a 3 Tesla (3T) magnet. Both
systems provide IMRIS' patented technology and utilize 70 cm wide bore
advanced magnetic resonance imaging systems from Siemens.
    The 3T IMRISneuro provides higher quality advanced imaging techniques for
surgical planning such as diffusion tensor imaging (DTI), functional MRI and
spectroscopy as well as superior quality vascular imaging in a robust platform
specifically designed for use in an operating room. This additional system
provides hospitals with more choice to meet the unique and growing needs of
intraoperative and interventional imaging.
    "Just three years after the successful commercialization of our first
advanced intraoperative imaging product, IMRIS continues to revolutionize the
field with this latest addition of a 3T wide bore magnet to the IMRISneuro
family of surgical imaging solutions," said David Graves, President and CEO of
IMRIS. "We believe the 3T IMRISneuro system is the most advanced surgical
imaging technology available today, providing physicians with timely access to
information that can measurably improve the outcome of interventional and
surgical procedures."
    Mr. Graves continued, "This latest addition to the IMRISneuro platform
further demonstrates that IMRIS is at the very leading edge of innovative
imaging technology development, and provides another indication of our
continuing commitment to improving patient outcomes."
    The 3T IMRISneuro has also been approved in Canada, with the first system
delivered to Foothills Hospital in Calgary, Alberta in November 2008.
Previously, Foothills Hospital led the way in intraoperative MR imaging by
being the first in the world to choose the 1.5T IMRISneuro system.

    About IMRIS

    IMRIS (TSX: IM) is a global leader in providing fully integrated,
advanced surgical imaging solutions. The company's flagship product,
IMRISneuro, utilizes patented technology that allows a high field MRI scanner
to be moved in to the operating room on demand, providing imaging during the
surgical procedure without compromising patient safety. This unique and
innovative system has been validated by leading neurosurgeons for use in
world-class neuroscience centers.
    For more information, visit www.imris.com.




For further information: Susan McLeod, Manager, Marketing,
Communications, IMRIS Inc., Tel: (204) 480-7094, Email: smcleod@imris.com